Adjunctive Minocycline in Acute Ischemic Stroke: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Brain and Behavior · 2026-07 · 16 (7)
DOI: 10.1002/brb3.71576 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Brain and Behavior, online erschienen am 09.07.2026. Verfasst von Samaha Khalid und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Foundation University Medical College, Islamabad, Pakistan. Hauptthemen laut MEDLINE: Minocycline, Ischemic Stroke, Neuroprotective Agents, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Acute ischemic stroke (AIS) is a leading cause of mortality and long‐term disability worldwide. Despite advances in acute stroke management, many patients continue to experience substantial neurological disability and incomplete recovery. Minocycline, a tetracycline antibiotic with anti‐inflammatory and neuroprotective properties and good blood–brain barrier penetration, has been investigated as a potential adjunctive therapy in AIS.
Methods
A systematic search of major databases was conducted identifying randomized controlled trials evaluating minocycline in patients with AIS. Outcomes included functional and neurological recovery assessed using the modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS), and Barthel index (BI), as well as mortality and vascular events. Pooled effect estimates were calculated using random‐effects meta‐analysis.
Results
Seven RCTs comprising 2197 patients were included, with 1093 receiving minocycline and 1104 receiving placebo or standard care. Functional independence at 3 months (mRS 0–2) showed no significant difference between groups (RR 1.28, 95% CI 0.97–1.69; I 2 = 84.9%). Minocycline was associated with lower NIHSS scores (MD −2.45, 95% CI −4.32 to −0.59; I 2 = 88.6%) and higher BI scores (MD 12.52, 95% CI 6.28–18.76; I 2 = 47.0%). Mortality (RR 0.66, 95% CI 0.39–1.090 and stroke recurrence or MI showed no significant differences (RR 0.97, 95% CI 0.69–1.37).
Conclusions
Although a consistent improvement in functional independence was not demonstrated, minocycline showed signals of benefit in selected neurological outcomes with a favorable safety profile. These findings support the need for adequately powered, multicenter randomized trials to clarify its therapeutic role.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Foundation University Medical College, Islamabad, Pakistan.
- Medical College, Aga Khan University, Karachi, Pakistan.
- Department of ENT and Head and Neck Surgery, Benazir Bhutto Hospital, Rawalpindi, Pakistan.
- Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
- National Academy of Medical Sciences, Bir Hospital, Kathmandu, Nepal.
ORCID-Profile: Samaha Khalid, Malik Aon Ali Abbas, Muhammad Sohaib Shahid, Muhammad Nihal Moarij Azeem Malik, Mahnoor Javed, Saad Ashraf, Muhammad Daoud Tariq, Deepak Rai
Zitieren
APA
Khalid, S., Abbas, M. A. A., Shahid, M. S., Malik, M. N. M. A., Javed, M., Rehman, A., Ashraf, S., Tariq, M. D., & Rai, D. (2026). Adjunctive Minocycline in Acute Ischemic Stroke: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Brain and Behavior, 16(7). https://doi.org/10.1002/brb3.71576
Vancouver
Khalid S, Abbas MAA, Shahid MS, Malik MNMA, Javed M, Rehman A, et al. Adjunctive Minocycline in Acute Ischemic Stroke: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Brain and Behavior. 2026;16(7). doi:10.1002/brb3.71576
BibTeX
@article{Khalid2026,
author = {Khalid, Samaha and Abbas, Malik Aon Ali and Shahid, Muhammad Sohaib and Malik, Muhammad Nihal Moarij Azeem and Javed, Mahnoor and Rehman, Abdur and Ashraf, Saad and Tariq, Muhammad Daoud and Rai, Deepak},
title = {Adjunctive Minocycline in Acute Ischemic Stroke: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
journal = {Brain and Behavior},
year = {2026},
volume = {16},
number = {7},
doi = {10.1002/brb3.71576}
}
EUVIMED